The T2Candida® Panel revolutionizes the detection of sepsis pathogens. It is the first sepsis pathogen diagnostic panel requiring no blood culture, delivering faster, easier and accurate results in an average of 4.3 hours.1 Run on the fully-automated T2Dx Instrument, the T2Candida Panel identifies the five clinically relevant species of Candida directly from whole blood which enables physicians to initiate appropriate therapy on day zero.
All other FDA-cleared Candida diagnostics require a blood culture to determine the Candida species. Blood culture, however, is hampered by a sensitivity of 50% and a lag time of up to 2 to 6 days for species identification or negative result.2
The T2Candida Panel and the T2Dx Instrument completely change sepsis pathogen detection and treatment, thanks to groundbreaking T2 Magnetic Resonance technology (T2MR), the first technology capable of sepsis pathogen detection directly in whole blood.
The T2Candida Panel delivers:
- 91.1% Sensitivity1
- 99.4% Specificity1
- Limits of detection as low as 1 CFU/mL1
- Species-specific results in an average of 4.3 hours directly from whole blood1
- Accuracy even in the presence of antimicrobials
The T2Candida Panel detects the following species of Candida direct from whole blood: C. albicans, C. tropicalis, C. parapsilosis, C. krusei and C. glabrata.
A positive T2Candida Panel result enables clinicians to quickly treat patients with appropriate therapy – reducing costs, adverse outcomes and patient mortality.
A negative T2Candida Panel result enables physicians to avoid unnecessary antifungal use – reducing antimicrobial costs, toxicity and resistance.